Harnessing the Potential of Vesicular Stomatitis Virus as a Novel Therapeutic Strategy for Cancer Treatment

Oncolytic virotherapy has emerged as a promising approach for the treatment of various cancers. This review article aims to provide an overview of Vesicular Stomatitis Virus (VSV) as an emerging anti-cancer therapy.

The article discusses the mechanism of action, preclinical and clinical studies, and challenges in the clinical translation of VSV. It also explores potential strategies to enhance the efficacy and safety of VSV-based oncolytic therapy, including combination therapies and genetic modifications

The mechanisms underlying VSV-mediated anti-cancer activity, such as induction of apoptosis, activation of immune responses, and disruption of tumor vasculature, are explored. Additionally, known methods for the preparation of oncolytic VSV, including genetic modifications and combination therapies, are discussed to optimize its anti-cancer effects.

Strategies to enhance VSV efficacy and overcome safety challenges are examined, including the use of VSV in combination with other therapies, such as chemotherapy or immunotherapy, as well as the development of novel viral vectors and engineering approaches to improve tumor-specific targeting and minimize off-target effects. In conclusion, this review highlights the potential of VSV as a novel therapeutic strategy for cancer treatment. Harnessing the unique characteristics of VSV, combined with ongoing research and technological advancements, may pave the way for the development of effective and safe VSV-based therapies in the future.